Biotech Values

[Whalatane]

Blade. re ALNA ...Co is going to run out of $ late 2020 and results to date may not be as great as Co hypes
eg
URIROX-1 achieved its primary endpoint, with a mean reduction of 22.6% in average 24-hour UOx excretion measured during Weeks 1-4 in patients on reloxaliase, compared to 9.7% in patients on placebo (least square (LS) mean treatment difference of -14.3%,. p=0.004).

Secondary endpts were not stat sig .
JMO
Kiwi